As the use of GLP-1s has surged across the United States, the average total payments per user have also climbed sharply, a new study reveals. Rise of GLP-1s raise affordability questionsBy the numbers:According to the study’s findings, the use of GLP-1 medications among U.S. adults without diabetes increased more than sixfold between 2017 and 2022. GLP-1 use surgesBig picture view:The findings come as policymakers and insurers grapple with the growing demand for GLP-1 drugs. Earlier this month, Medicare launched a temporary program allowing millions of eligible seniors to access GLP-1 medications for a flat $50 monthly copayment. Since the FDA approved Wegovy in 2021 and Zepbound in 2023, public awareness of GLP-1 drugs have surged.